Companies › Tetraphase Pharmaceuticals
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 4; Infectious disease, Oncology; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eravacycline Bacterial 70S ribosome inhibitor | – | Phase 2 | Complicated Intra-abdominal Infections (cIAI); Infections, Bacterial; Hematological Malignancy | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06440304 | Eravacycline | Phase 4 | Infections, Bacterial | Infectious disease | Dec 2026 |
| NCT05537896 | Eravacycline | Phase 2 | Hematological Malignancy | Oncology | Feb 2028 |
| NCT06794541 | Eravacycline | Phase 2 | Complicated Intra-abdominal Infections (cIAI) | Infectious disease | Feb 2029 |
No annotated target.
–
Amivas Cantex Pharmaceuticals The Skin Center Dermatology Group NanoEcho Syncromune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.